ROCKFORD (WREX) — OSF HealthCare is now offering the Invenia ABUS 2.0 (Automated Breast Ultrasound System).
ABUS is approved by the Food and Drug Administration (FDA) for breast cancer screening as an adjunct to mammography for women with dense breast tissue.
According to studies published in JAMA (the Journal of the American Medical Association), dense breast tissue has been found to be the most common risk factor for the development of cancer and also makes cancer more difficult to detect using mammography.
The difficulty that many radiologists experience when reading mammograms is that both dense tissue and cancer appear white on a mammogram. With ABUS, suspicious masses appear black against the white dense tissue.
In early 2019, a national density inform law was passed that mandates that the FDA update mammography reporting so that women be notified if their breasts are dense. Providers may offer supplemental imaging as appropriate to help find cancers hiding in dense breast tissue.
“We are excited to add the upgraded ABUS screening tool to our comprehensive breast cancer screening program. By offering ABUS in addition to mammography for our patients with dense breast tissue, we anticipate improving detection for small cancers that cannot be seen on a mammogram alone in these women. We believe ABUS will become an integral part of our practice for the detection of breast cancer,” said Allison Gleason, Supervisor Mammography and Ultrasound.
It is recommended women get regular mammograms beginning at age 40 or earlier depending on family history. If they have been told that they have dense breast tissue, they should talk to their doctor or radiologist about their specific risk and additional screening tests that might be appropriate.